Oramed Pharmaceuticals Inc.
ORMP
$4.48
$0.102.28%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 488.17% | 601.31% | 198.23% | 346.67% | 44.25% |
| Total Depreciation and Amortization | 3.33% | 0.00% | -3.23% | -40.38% | -44.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -394.77% | -966.03% | -235.37% | -650.24% | -51.66% |
| Change in Net Operating Assets | -205.46% | 597.01% | 4,160.00% | 487.97% | -220.94% |
| Cash from Operations | 94.34% | 17.16% | 75.61% | 77.12% | -270.28% |
| Capital Expenditure | 50.00% | -66.67% | 81.82% | 100.00% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 107.86% | -182.49% | -110.90% | 212.00% | -157.95% |
| Cash from Investing | 107.86% | -182.52% | -110.92% | 211.98% | -157.95% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -404.31% | -- | -235.48% | 72.04% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -425.34% | -- | -235.48% | 72.04% | 98.79% |
| Foreign Exchange rate Adjustments | -395.00% | 2,300.00% | -3,550.00% | 33.33% | 1,100.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 103.48% | -262.94% | -150.60% | 185.31% | -188.73% |